240206
Nicotinamide
≥99%
Synonym(s):
Niacinamide, Nicotinic acid amide, Pyridine-3-carboxylic acid amide, Vitamin B3, Vitamin PP
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C6H6N2O
CAS Number:
Molecular Weight:
122.12
EC Number:
202-713-4
UNSPSC Code:
12352200
MDL number:
Beilstein/REAXYS Number:
383619
assay
≥99%
mp
128-131 °C (lit.)
SMILES string
NC(=O)c1cccnc1
InChI
1S/C6H6N2O/c7-6(9)5-2-1-3-8-4-5/h1-4H,(H2,7,9)
InChI key
DFPAKSUCGFBDDF-UHFFFAOYSA-N
Biochem/physiol Actions
Nicotinamide is an amide derivative of vitamin B3 and a PARP inhibitor
Still not finding the right product?
Explore all of our products under Nicotinamide
signalword
Warning
hcodes
Hazard Classifications
Eye Irrit. 2
Storage Class
11 - Combustible Solids
wgk
WGK 1
flash_point_f
302.0 °F - closed cup
flash_point_c
150 °C - closed cup
ppe
dust mask type N95 (US), Eyeshields, Gloves
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Mitchell E Horwitz et al.
The Journal of clinical investigation, 124(7), 3121-3128 (2014-06-10)
Delayed hematopoietic recovery is a major drawback of umbilical cord blood (UCB) transplantation. Transplantation of ex vivo-expanded UCB shortens time to hematopoietic recovery, but long-term, robust engraftment by the expanded unit has yet to be demonstrated. We tested the hypothesis
Robert J Motzer et al.
The Lancet. Oncology, 14(6), 552-562 (2013-04-20)
In a phase 3 trial comparing the efficacy and safety of axitinib versus sorafenib as second-line treatment for metastatic renal cell carcinoma, patients given axitinib had a longer progression-free survival (PFS). Here, we report overall survival and updated efficacy, quality
Marie-Hélène Massicotte et al.
European journal of endocrinology, 170(4), 575-582 (2014-01-16)
Tyrosine kinase inhibitors (TKIs) are used to treat patients with advanced thyroid cancers. We retrospectively investigated the efficacy of TKIs administered outside of clinical trials in metastatic sites or locally advanced thyroid cancer patients from five French oncology centers. THERE